Emicizumab

Information about Emicizumab

Emicizumab is a humanized bispecific monoclonal antibody to two human coagulation factors – factor IXa and factor X – that mimics the activity of factor VIII and is used to prevent bleeding episodes in patients with severe hemophilia A (which is caused by factor VIII deficiency).

Liver safety of Emicizumab

Emicizumab has not been linked to serum enzyme elevations during therapy or to instances of idiosyncratic acute liver injury.

Mechanism of action of Emicizumab

Emicizumab (e" mi ciz' ue mab) is a recombinant, humanized, bispecific monoclonal antibody to two human coagulation factors – factor IXa and factor X – that is used to prevent bleeding episodes in patients with severe hemophilia A. Hemophilia A is a serious genetic disease associated with deficiency in product of factor VIII leading to recurrent episodes of bleeding that result in major disability and premature death. Hemophilia A is typically treated with infusions of factor VIII isolated and concentrated from human plasma or produced by recombinant techniques. Some patients given factor VIII infusions, however, develop neutralizing antibodies which inhibit the anticoagulation activity of the infusions. Emicizumab is a recombinant bispecific monoclonal antibody that binds to both factor IXa and X, which mimics the co-factor function of factor VIII, bypassing its need in the coagulation cascade.

Clinical use of Emicizumab

In clinical trials, emicizumab was found to reduce bleeding episodes in patients with hemophilia A and antibodies to factor VIII.

FDA approval information for Emicizumab

Emicizumab was approved for use for this indication in the United States in 2017.

Dosage and administration for Emicizumab

Emicizumab is available as a solution in single dose vials of 30, 60, 105 and 150 mg under the commercial name Hemlibra. The recommended dose is 3 mg/kg by subcutaneous injection once weekly for 4 weeks, followed by 1.5 mg/kg weekly.

Side effects of Emicizumab

Side effects are not common, but can include headache, arthralgia and infection site reactions. Rare, but potentially severe adverse reactions may include hypersensitivity reactions and thromboembolic events.

genetic disorder agents

cystic fibrosis agents

• ivacaftor
• lumacaftor
• cystinosis agents
• cysteamine

enzyme replacement therapy

• gaucher disease agents
  • glucocerebrosidase (enzyme replacement therapy)
  • imiglucerase, taliglucerase alfa, velaglucerase alfa

glucosylceramide synthase inhibitors (substrate restriction therapy)

• eliglustat, miglustat

lysosomal acid lipase deficiency agents

• sebelipase alfa

miscellaneous

• agalsidase beta, alglucosidase alfa, alpha1-proteinase inhibitor, elosulfase alfa, galsulfase, idursulfase, laronidase, pegademase

homocystinuria agents

• betaine

Huntington disease agents

• Tetrabenazine

• • Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors
    • Deutetrabenazine, Tetrabenazine, Valbenazine

Monoclonal Antibodies

• Burosumab

Tyrosinemia Agents

• Nitisinone

Urea Cycle Disorder Agents

• Carglumic acid, Lactulose, Phenylbutyrate, Rifaximin, Sodium benzoate

Hematologic Agents

• Eculizumab, Emapalumab, Emicizumab, Lanadelumab, Ravulizumab

The article on Emicizumab is a stub. YOU can help Wikimd by expanding it!

Medication resources

WikiMD is a sponsored by W8MD Weight loss, sleep and medical aesthetics.

Learn more

• Dailymed label info
• Scientific articles

edit 

About WikiMD

About us: WikiMD is a free medical encyclopedia and wellnesspedia moderated by medical professionals.

Our mission: Provide up to date physician reviewed health, nutrition and wellness information for free in over 100 languages.

Join us: This article is a stub. Help improve Emicizumab or others. Do not trust amateurs with your life! Join us in this effort!. Paid editors welcome.